JPY 994.0
(-0.1%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.01 Billion JPY | -3.27% |
2022 | 1.04 Billion JPY | 40.13% |
2021 | 746.11 Million JPY | 15.36% |
2020 | 646.75 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 908.55 Million JPY | -10.16% |
2024 Q2 | 913.71 Million JPY | 0.57% |
2023 Q3 | 930.96 Million JPY | -4.59% |
2023 FY | 1.01 Billion JPY | -3.27% |
2023 Q4 | 1.01 Billion JPY | 8.63% |
2023 Q2 | 975.76 Million JPY | -1.34% |
2023 Q1 | 988.99 Million JPY | -5.45% |
2022 FY | 1.04 Billion JPY | 40.13% |
2022 Q4 | 1.04 Billion JPY | 9.12% |
2022 Q3 | 958.53 Million JPY | 0.0% |
2021 FY | 746.11 Million JPY | 15.36% |
2020 FY | 646.75 Million JPY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 95.953% |
Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.987% |
Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 99.865% |
Shionogi & Co., Ltd. | 164.35 Billion JPY | 99.385% |
Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | 70.211% |
Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 97.641% |
Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 96.371% |
Eisai Co., Ltd. | 494.82 Billion JPY | 99.796% |
Morishita Jintan Co., Ltd. | 5.04 Billion JPY | 79.934% |
Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 98.361% |
Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 96.72% |
Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 97.459% |
Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 96.746% |
Tsumura & Co. | 132.88 Billion JPY | 99.239% |
Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 97.458% |
Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 92.394% |
Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 99.632% |
Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 97.71% |
Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 98.57% |
KYORIN Holdings, Inc. | 46.89 Billion JPY | 97.843% |
Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | 85.558% |
Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 96.024% |
SymBio Pharmaceuticals Limited | 8.14 Billion JPY | 87.579% |
MedRx Co., Ltd | 129 Million JPY | -683.984% |
Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | 69.096% |
Solasia Pharma K.K. | 673 Million JPY | -50.273% |
Modalis Therapeutics Corporation | 645.5 Million JPY | -56.675% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 96.777% |
Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 99.383% |
Toho Holdings Co., Ltd. | 523.98 Billion JPY | 99.807% |
Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | 85.453% |